The IMPACT grant includes a clinical trial that targets patients with non-small cell lung cancer who have recurrent pleural effusion (frequent re-accumulation of fluid around the lungs). Patients who meet all the eligibility criteria will be enrolled into the trial and will undergo placement of a catheter within the space around the lungs. The catheter enables doctors to remove fluid whenever necessary without discomfort to the patient. Patients will then be assigned randomly to receive a new investigational drug called ZD6474 or a placebo (sugar pill). Patients will be treated for 10 weeks.
This study seeks to determine if ZD6474 has a beneficial effect, that is, if the drug decreases re-accumulation of fluid around the lungs such that the catheter can be removed in a shorter period of time.